Healthy Skepticism Library item: 1807

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: news

Company News; Glaxo Seeks F.D.A. Approval Of Depression Treatment
2002 Aug 30

Full text:

GlaxoSmithKline, the drug maker, said yesterday that it had filed for approval of its Lamictal epilepsy drug as a treatment for recurring depression. Glaxo sought Food and Drug Administration permission to market the drug for long-term bipolar I disorders, which cause mood swings in patients, the company said. About 2.3 million people in the United States have the condition, Glaxo said.